Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 84

1.

NEO212, a conjugate of temozolomide and perillyl alcohol, blocks the endothelial-to-mesenchymal transition in tumor-associated brain endothelial cells in glioblastoma.

Marín-Ramos NI, Jhaveri N, Thein TZ, Fayngor RA, Chen TC, Hofman FM.

Cancer Lett. 2019 Feb 1;442:170-180. doi: 10.1016/j.canlet.2018.10.034. Epub 2018 Oct 28.

PMID:
30392789
2.

NEO212 Inhibits Migration and Invasion of Glioma Stem Cells.

Marín-Ramos NI, Thein TZ, Cho HY, Swenson SD, Wang W, Schönthal AH, Chen TC, Hofman FM.

Mol Cancer Ther. 2018 Mar;17(3):625-637. doi: 10.1158/1535-7163.MCT-17-0591. Epub 2018 Feb 13.

3.

A novel drug conjugate, NEO212, targeting proneural and mesenchymal subtypes of patient-derived glioma cancer stem cells.

Jhaveri N, Agasse F, Armstrong D, Peng L, Commins D, Wang W, Rosenstein-Sisson R, Vaikari VP, Santiago SV, Santos T, Chen L, Schönthal AH, Chen TC, Hofman FM.

Cancer Lett. 2016 Feb 28;371(2):240-50. doi: 10.1016/j.canlet.2015.11.040. Epub 2015 Dec 9.

PMID:
26683773
4.

NEO212, temozolomide conjugated to perillyl alcohol, is a novel drug for effective treatment of a broad range of temozolomide-resistant gliomas.

Cho HY, Wang W, Jhaveri N, Lee DJ, Sharma N, Dubeau L, Schönthal AH, Hofman FM, Chen TC.

Mol Cancer Ther. 2014 Aug;13(8):2004-17. doi: 10.1158/1535-7163.MCT-13-0964. Epub 2014 Jul 3.

5.

Endothelial cells from different anatomical origin have distinct responses during SNAIL/TGF-β2-mediated endothelial-mesenchymal transition.

Pinto MT, Ferreira Melo FU, Malta TM, Rodrigues ES, Plaça JR, Silva WA Jr, Panepucci RA, Covas DT, de Oliveira Rodrigues C, Kashima S.

Am J Transl Res. 2018 Dec 15;10(12):4065-4081. eCollection 2018.

6.

Endothelial Mesenchymal Transition: Comparative Analysis of Different Induction Methods.

Pinto MT, Covas DT, Kashima S, Rodrigues CO.

Biol Proced Online. 2016 Apr 27;18:10. doi: 10.1186/s12575-016-0040-3. eCollection 2016.

7.

Endothelial-to-mesenchymal transition: Cytokine-mediated pathways that determine endothelial fibrosis under inflammatory conditions.

Pérez L, Muñoz-Durango N, Riedel CA, Echeverría C, Kalergis AM, Cabello-Verrugio C, Simon F.

Cytokine Growth Factor Rev. 2017 Feb;33:41-54. doi: 10.1016/j.cytogfr.2016.09.002. Epub 2016 Sep 23. Review.

PMID:
27692608
8.

Molecular Analysis of Endothelial-mesenchymal Transition Induced by Transforming Growth Factor-β Signaling.

Suzuki HI, Horie M, Mihira H, Saito A.

J Vis Exp. 2018 Aug 3;(138). doi: 10.3791/57577.

PMID:
30124659
9.

MicroRNA-31 is a positive modulator of endothelial-mesenchymal transition and associated secretory phenotype induced by TGF-β.

Katsura A, Suzuki HI, Ueno T, Mihira H, Yamazaki T, Yasuda T, Watabe T, Mano H, Yamada Y, Miyazono K.

Genes Cells. 2016 Jan;21(1):99-116. doi: 10.1111/gtc.12323. Epub 2015 Dec 10.

10.

The mechanism of TGF-β/miR-155/c-Ski regulates endothelial-mesenchymal transition in human coronary artery endothelial cells.

Wang J, He W, Xu X, Guo L, Zhang Y, Han S, Shen D.

Biosci Rep. 2017 Aug 23;37(4). pii: BSR20160603. doi: 10.1042/BSR20160603. Print 2017 Aug 31.

11.

Kaposi sarcoma herpesvirus promotes endothelial-to-mesenchymal transition through Notch-dependent signaling.

Gasperini P, Espigol-Frigole G, McCormick PJ, Salvucci O, Maric D, Uldrick TS, Polizzotto MN, Yarchoan R, Tosato G.

Cancer Res. 2012 Mar 1;72(5):1157-69. doi: 10.1158/0008-5472.CAN-11-3067. Epub 2012 Jan 11.

12.

Contribution of Endothelial-to-Mesenchymal Transition to the Pathogenesis of Human Cerebral and Orbital Cavernous Malformations.

Takada S, Hojo M, Tanigaki K, Miyamoto S.

Neurosurgery. 2017 Jul 1;81(1):176-183. doi: 10.1093/neuros/nyx078.

PMID:
28368503
13.

Relaxin inhibits cardiac fibrosis and endothelial-mesenchymal transition via the Notch pathway.

Zhou X, Chen X, Cai JJ, Chen LZ, Gong YS, Wang LX, Gao Z, Zhang HQ, Huang WJ, Zhou H.

Drug Des Devel Ther. 2015 Aug 11;9:4599-611. doi: 10.2147/DDDT.S85399. eCollection 2015. Erratum in: Drug Des Devel Ther. 2017 Apr 10;11:1159.

14.

Losartan inhibits endothelial-to-mesenchymal transformation in mitral valve endothelial cells by blocking transforming growth factor-β-induced phosphorylation of ERK.

Wylie-Sears J, Levine RA, Bischoff J.

Biochem Biophys Res Commun. 2014 Apr 18;446(4):870-5. doi: 10.1016/j.bbrc.2014.03.014. Epub 2014 Mar 12.

15.
16.

A small population of liver endothelial cells undergoes endothelial-to-mesenchymal transition in response to chronic liver injury.

Ribera J, Pauta M, Melgar-Lesmes P, Córdoba B, Bosch A, Calvo M, Rodrigo-Torres D, Sancho-Bru P, Mira A, Jiménez W, Morales-Ruiz M.

Am J Physiol Gastrointest Liver Physiol. 2017 Nov 1;313(5):G492-G504. doi: 10.1152/ajpgi.00428.2016. Epub 2017 Aug 10.

17.

A novel temozolomide analog, NEO212, with enhanced activity against MGMT-positive melanoma in vitro and in vivo.

Chen TC, Cho HY, Wang W, Nguyen J, Jhaveri N, Rosenstein-Sisson R, Hofman FM, Schönthal AH.

Cancer Lett. 2015 Mar 28;358(2):144-151. doi: 10.1016/j.canlet.2014.12.021. Epub 2014 Dec 15.

PMID:
25524552
18.

RUNX3 modulates hypoxia-induced endothelial-to-mesenchymal transition of human cardiac microvascular endothelial cells.

Liu Y, Zou J, Li B, Wang Y, Wang D, Hao Y, Ke X, Li X.

Int J Mol Med. 2017 Jul;40(1):65-74. doi: 10.3892/ijmm.2017.2998. Epub 2017 May 22.

19.

Celastrol protects TGF-β1-induced endothelial-mesenchymal transition.

Gong F, Zhao F, Gan XD.

J Huazhong Univ Sci Technolog Med Sci. 2017 Apr;37(2):185-190. doi: 10.1007/s11596-017-1713-0. Epub 2017 Apr 11.

PMID:
28397045
20.

Endothelial-mesenchymal transition of brain endothelial cells: possible role during metastatic extravasation.

Krizbai IA, Gasparics Á, Nagyőszi P, Fazakas C, Molnár J, Wilhelm I, Bencs R, Rosivall L, Sebe A.

PLoS One. 2015 Mar 30;10(3):e0123845. doi: 10.1371/journal.pone.0123845. eCollection 2015.

Supplemental Content

Support Center